Compare ORIS & NMTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ORIS | NMTC |
|---|---|---|
| Founded | 2014 | 2009 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Medical/Dental Instruments |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.2M | 45.5M |
| IPO Year | 2024 | N/A |
| Metric | ORIS | NMTC |
|---|---|---|
| Price | $1.49 | $0.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $2.23 |
| AVG Volume (30 Days) | ★ 631.8K | 370.9K |
| Earning Date | 04-30-2026 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $12,317,000.00 | $12,097,692.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $32.08 |
| P/E Ratio | $198.58 | ★ N/A |
| Revenue Growth | N/A | ★ 250.35 |
| 52 Week Low | $1.11 | $0.40 |
| 52 Week High | $45.60 | $1.39 |
| Indicator | ORIS | NMTC |
|---|---|---|
| Relative Strength Index (RSI) | 64.43 | 56.03 |
| Support Level | $1.34 | $0.85 |
| Resistance Level | $1.87 | $0.94 |
| Average True Range (ATR) | 0.20 | 0.08 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 44.74 | 53.38 |
Oriental Rise Holdings Ltd is an integrated supplier of tea products in China. It is principally engaged in the business of planting, cultivating, processing, and selling processed tea. The company currently produces and sells three categories of products: roughly processed white tea, roughly processed black tea, and refined tea. The company's business operations are vertically integrated, covering cultivation, processing of tea leaves, and the sale of tea products to tea business operators and end-user retail customers. Geographically, the company generates all of its revenue from its business in the People's Republic of China (the PRC).
NeuroOne Medical Technologies Corp is focused on diagnostic, ablation, and deep brain stimulation technology for brain-related conditions such as epilepsy and Parkinson's disease; ablation and stimulation for pain management; and drug delivery with diagnostic and stimulation capabilities. It develops thin film electrode technology for various recording and therapeutic applications, crucial for diagnosing neurological disorders such as epilepsy, Parkinson's disease, dystonia, and essential tremors. The company operates in one segment, developing and commercializing products for neuromodulation, cEEG, and sEEG recording, monitoring, ablation, and brain stimulation, with revenue from Evo Cortical, Evo sEEG, and OneRF Ablation System.